42 views
– We have a drug that stops the progression of the disease (ALS-SOD1 – editor's note) and leads to a reduction or even halt in the growth of disability. For those patients for whom it is dedicated, it is definitely a breakthrough – says Prof. Magdalena Kuźma-Kozakiewicz from the Department of Neurology of the Medical University of Warsaw in an interview with Medexpress. The treatment is currently being carried out as part of the early access to therapy program.